Structural Heart

Abbott Structural Heart is a leading global business unit within Abbott Laboratories dedicated to developing minimally invasive treatments for structural heart diseases. The company's portfolio features industry-standard technologies such as the MitraClip for transcatheter mitral valve repair and the Amplatzer family of occluders for congenital heart defects. By focusing on transcatheter aortic valve replacement (TAVR) and innovative repair solutions for the mitral and tricuspid valves, Abbott Structural Heart aims to provide alternatives to open-heart surgery. Their products are designed to improve clinical outcomes and quality of life for patients suffering from complex valvular and structural cardiac conditions.